An injection of triamcinolone acetonide-moxifloxacin controlled intraocular inflammation and corneal edema after cataract surgery.
The retrospective longitudinal comparative study included 681 eyes (group 1) that received Tri-Moxi (triamcinolone acetonide-moxifloxacin, Imprimis Pharmaceuticals) and an NSAID after undergoing cataract surgery. This group was compared with 514 eyes (group 2) that received a standard eye drop therapy of antibiotic, corticosteroid and NSAID after cataract surgery.
Researchers evaluated postoperative inflammation, corneal edema and the rate of high IOP between the
Uncategorized